Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination

接种 BNT162b2 疫苗后,抗刺突蛋白抗体水平较低的人群出现淋巴细胞过早老化的证据

阅读:5
作者:Yapei Huang, Juliana E Shin, Alexander M Xu, Changfu Yao, Sandy Joung, Min Wu, Ruan Zhang, Bongha Shin, Joslyn Foley, Simeon B Mahov, Matthew E Modes, Joseph E Ebinger, Matthew Driver, Jonathan G Braun, Caroline A Jefferies, Tanyalak Parimon, Chelsea Hayes, Kimia Sobhani, Akil Merchant, Sina A Ghari

Abstract

SARS-CoV-2 vaccines have unquestionably blunted the overall impact of the COVID-19 pandemic, but host factors such as age, sex, obesity, and other co-morbidities can affect vaccine efficacy. We identified individuals in a relatively healthy population of healthcare workers (CORALE study cohort) who had unexpectedly low peak anti-spike receptor binding domain (S-RBD) antibody levels after receiving the BNT162b2 vaccine. Compared to matched controls, "low responders" had fewer spike-specific antibody-producing B cells after the second and third/booster doses. Moreover, their spike-specific T cell receptor (TCR) repertoire had less depth and their CD4+ and CD8+T cell responses to spike peptide stimulation were less robust. Single cell transcriptomic evaluation of peripheral blood mononuclear cells revealed activation of aging pathways in low responder B and CD4+T cells that could underlie their attenuated anti-S-RBD antibody production. Premature lymphocyte aging may therefore contribute to a less effective humoral response and could reduce vaccination efficacy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。